Halaven (eribulin mesylate) / Eisai 
Welcome,         Profile    Billing    Logout  
 71 Diseases   127 Trials   127 Trials   3064 News 


12345678910111213...4243»
  • ||||||||||  Abnormal cardiac accumulation on FDG PET due to chemotherapy for breast cancer (e-Poster Area) -  Sep 12, 2025 - Abstract #EANM2025EANM_2153;    
    Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2025 --> Apr 2026 Imaging Evaluation Two nuclear medicine physicians assessed: RV/atrium uptake (abnormal focal)(FIgure.3) Homogeneous LV pattern (diffuse uniform uptake)(Figure.4) Myocardial SUVmax Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis Fisher
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Trial completion, Enrollment change:  PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) -  Sep 10, 2025   
    P3,  N=226, Completed, 
    Imaging Evaluation Two nuclear medicine physicians assessed: RV/atrium uptake (abnormal focal)(FIgure.3) Homogeneous LV pattern (diffuse uniform uptake)(Figure.4) Myocardial SUVmax Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis Fisher Unknown status --> Completed | N=370 --> 226
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
    Trial completion:  A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) -  Aug 28, 2025   
    P2,  N=57, Completed, 
    No ADA against MORAb-202 was detected in postdose samples. Active, not recruiting --> Completed
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal:  KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells. (Pubmed Central) -  Aug 15, 2025   
    For the first time, we show that knockdown of vimentin and eribulin treatment can restore E-cadherin and reverse epithelial-to-mesenchymal transition in KSHV- and HPV31-infected oral epithelial cells. These findings fill a gap in our understanding of oncogenesis and metastasis of oral cancers caused by KSHV and HPV31, revealing that vimentin may serve as a potential therapeutic molecular target for KSHV- and HPV-associated oral cancer.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
    P2 data, Journal:  An open-label phase II study: The efficiency and safety of anlotinib?+?eribulin in patients with HER2-negative metastatic breast cancer. (Pubmed Central) -  Aug 11, 2025   
    P2
    The most common treatment-related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Neulasta (pegfilgrastim) / Roche
    Journal:  Aortitis after granulocyte-colony stimulating factor administration: A case report. (Pubmed Central) -  Aug 8, 2025   
    In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF...After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, Real-world evidence:  Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting. (Pubmed Central) -  Aug 7, 2025   
    Overall, the study shows low response rate with manageable toxicity. The findings highlight the need for further focused studies comparing eribulin with existing chemotherapies, especially in the Indian patients with disease heterogeneity and unique genetic makeup.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date:  Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) -  Aug 5, 2025   
    P2,  N=13, Active, not recruiting, 
    The addition of ipatasertib to capecitabine or eribulin Trial completion date: May 2025 --> Sep 2025
  • ||||||||||  Serial FDG PET analysis for detection of cardiotoxicity of breast cancer chemotherapy (Room 133+134) -  Aug 1, 2025 - Abstract #EANM2025EANM_584;    
    Trial completion date: May 2025 --> Sep 2025 M-SUR = SUVmean myocardium / SUVmean descending aorta Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis For patients receiving multiple regimens, data compared before/after each regimen Wilcoxon signed-rank test used for comparisons Results Study summary Average observation period: 39 months Average PET scans per patient: 5.0 Total pre/post datasets: 308 Anthracyclines: 34 (17 patients) ICI: 19 (9 patients) HER2 inhibitors: 146 (40 patients) Others: 109 (54 patients) Significant increase in M-SUR after chemotherapy(Figure.4) Anthracyclines: 5.37
  • ||||||||||  cisplatin/vinblastine/SHAO-FA (INT230-6) / Intensity Therap
    Enrollment closed:  A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (clinicaltrials.gov) -  Jul 29, 2025   
    P3,  N=333, Active, not recruiting, 
    M-SUR = SUVmean myocardium / SUVmean descending aorta Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis For patients receiving multiple regimens, data compared before/after each regimen Wilcoxon signed-rank test used for comparisons Results Study summary Average observation period: 39 months Average PET scans per patient: 5.0 Total pre/post datasets: 308 Anthracyclines: 34 (17 patients) ICI: 19 (9 patients) HER2 inhibitors: 146 (40 patients) Others: 109 (54 patients) Significant increase in M-SUR after chemotherapy(Figure.4) Anthracyclines: 5.37 Recruiting --> Active, not recruiting
  • ||||||||||  Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. (Pubmed Central) -  Jul 19, 2025   
    Key recommendations include weakly recommending CRT for large (??5?cm) nonmetastatic tumors, preferring drug modification over excision for residual lesions after CRT, and equally considering docetaxel, pazopanib, or eribulin for paclitaxel-resistant cases...Future directions emphasize the need for multicenter registry studies and prospective trials to refine treatment strategies. As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion:  Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer (clinicaltrials.gov) -  Jul 18, 2025   
    P2,  N=10, Completed, 
    As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care. Not yet recruiting --> Completed
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Clinical, Journal, Real-world evidence:  Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study. (Pubmed Central) -  Jun 24, 2025   
    The most frequently observed adverse events were hematological toxicity, with the majority classified as manageable in severity. The findings emphasize the potential of Eribulin in the treatment of HER2-negative advanced breast cancer, highlighting the need for further large-scale, prospective studies to refine and enhance treatment strategies.
  • ||||||||||  OQY-3258 / Oqory
    Trial completion date, Trial primary completion date:  A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov) -  Jun 19, 2025   
    P3,  N=378, Recruiting, 
    These findings support further clinical development of FZEC for EC treatment and highlight the complexity of the mechanisms of action of ADCs. Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jun 2027
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion, Trial completion date, Trial primary completion date:  Adaptive Therapy for Post-Second-Line Advanced Breast Cancer (clinicaltrials.gov) -  Jun 9, 2025   
    P2,  N=10, Completed, 
    Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jun 2027 Recruiting --> Completed | Trial completion date: Nov 2025 --> May 2025 | Trial primary completion date: Jul 2025 --> Sep 2024
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial initiation date, Trial primary completion date:  Arsenous Acid for Refractory Triple-Negative Breast Cancer (clinicaltrials.gov) -  Jun 6, 2025   
    P2,  N=12, Recruiting, 
    Phase classification: P2a --> P2 Trial completion date: Apr 2025 --> Oct 2026 | Initiation date: Apr 2024 --> Oct 2024 | Trial primary completion date: Sep 2024 --> Apr 2026